Gilead Sciences, Inc. (BIT:1GILD)
Italy flag Italy · Delayed Price · Currency is EUR
93.28
+0.79 (0.85%)
At close: May 13, 2025, 5:30 PM CET
52.47%
Market Cap 116.14B
Revenue (ttm) 26.59B
Net Income (ttm) 5.52B
Shares Out n/a
EPS (ttm) 4.38
PE Ratio 21.04
Forward PE 12.61
Dividend 2.87 (3.33%)
Ex-Dividend Date Mar 13, 2025
Volume 108
Average Volume 180
Open 93.28
Previous Close 92.49
Day's Range 93.28 - 93.28
52-Week Range 58.32 - 111.00
Beta 0.28
RSI 49.28
Earnings Date Apr 24, 2025

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p... [Read more]

Sector Healthcare
Founded 1987
Employees 17,600
Stock Exchange Borsa Italiana
Ticker Symbol 1GILD
Full Company Profile

Financial Performance

In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.

Financial numbers in USD Financial Statements

News

There is no news available yet.